Pfizer, BioNtech say flu-COVID shot generates strong immune response in trial By Reuters

© Reuters. A compagny brand is seen at a Pfizer workplace in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Picture

(Corrects syntax in headline)

(Reuters) -Pfizer and German companion BioNTech (NASDAQ:) stated on Thursday that their vaccine to stop flu and COVID-19 generated a robust immune response in opposition to strains of the viruses in an early- to mid-stage trial.

The businesses stated they plan to start out a late-stage trial within the coming months.

“This vaccine has the potential to reduce the impression of two respiratory illnesses with a single injection and should simplify immunization practices,” Annaliesa Anderson, Pfizer (NYSE:)’s head of vaccine analysis and improvement, stated in an announcement.

Within the trial, the vaccine candidates have been in comparison with a licensed influenza vaccine and the businesses’ up to date COVID-19 vaccine given on the identical go to.

The info from the trial confirmed that the flu-COVID vaccine demonstrated strong immune responses to influenza A, influenza B and SARS-CoV-2 strains, the businesses stated.